Why Iovance Biotherapeutics (IOVA) Stock Fell 2.04% in 10 Minutes After Q3 Earnings on Nov 5, 2026
EPS of -$0.05 came in above the -$0.09 estimate; revenue of $121.47 million came in above the $115.98 million estimate.
- IOVA fell 2.04% in the 10 minutes after the 07:09:23 ET headline, from $9.33 to $9.14.
- MoveSurge measured three earlier Iovance Biotherapeutics headlines with an attributed reaction between Aug 7, 2026 and Nov 4, 2026. The largest was -16.02% in 10 minutes, on Oct 29, 2026.
- 115,393 shares changed hands in those 10 minutes.
07:09:23 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| IOVA | 9.33 | 9.33 | 9.25 | 9.14 | -0.86% | -2.04% |
Iovance Biotherapeutics (IOVA) shares fell 2.04% in the 10 minutes after its Q3 results reached the MoveSurge news feed at 07:09:23 ET on Thursday, November 5, 2026. EPS of -$0.05 came in above the -$0.09 estimate; revenue of $121.47 million came in above the $115.98 million estimate.
IOVA in the first 10 minutes
The line that crossed at 07:09:23 ET: “IOVA Q3: EPS -0.05 vs -0.09 est; revenue USD 121.47mln vs USD 115.98mln est”
From a reference price of $9.33 just before the headline, the stock was down 0.86% after one minute and down 2.04%, at $9.14, after 10 minutes. The move kept building after the first minute. 115,393 shares changed hands in those 10 minutes. The headline crossed in pre-market trading, 2 hours 21 minutes before the 9:30 ET open.
Iovance Biotherapeutics Q3 results against estimates
| Measure | Reported | Estimate | Result |
|---|---|---|---|
| EPS | -$0.05 | -$0.09 | Beat |
| Revenue | $121.47 million | $115.98 million | Beat |
How IOVA traded after earlier earnings releases
| Report | EPS vs estimate | Revenue vs estimate | First move |
|---|---|---|---|
| Aug 6, 2026 | -$0.11 vs -$0.14 | $99.31 million vs $87.83 million | +2.90% in 15 min |
| May 7, 2026 | -$0.19 vs -$0.16 | $71.43 million vs $78.4 million | not measured |
Earlier IOVA headlines and the measured reaction
MoveSurge measured three earlier Iovance Biotherapeutics headlines with an attributed reaction between Aug 7, 2026 and Nov 4, 2026. The largest was -16.02% in 10 minutes, on Oct 29, 2026.
- Oct 29, 2026, 07:00 ET: “Iovance reports updated IOV-LUN-202 results and adds a precision TIL strategy for second-line metastatic non-small-cell lung cancer” (-16.02% in 10 minutes)
- Oct 23, 2026, 10:15 ET: “Iovance presents ESMO 2026 data showing deep, durable responses to lifileucel TIL cell therapy plus pembrolizumab in frontline advanced melanoma” (-1.29% in 10 minutes)
- Sep 29, 2026, 07:03 ET: “Iovance (IOVA) guidance update” (-1.29% in 10 minutes)
Iovance Biotherapeutics at a glance
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Market value | $3.94 billion (as of Nov 5, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
How did Iovance Biotherapeutics stock react to its Q3 earnings on November 5, 2026?
The stock fell 2.04% in the 10 minutes after its Q3 results crossed at 07:09:23 ET. EPS of -$0.05 came in above the -$0.09 estimate; revenue of $121.47 million came in above the $115.98 million estimate.
How far did IOVA move after the headline?
From $9.33 just before the headline to $9.14 10 minutes later, a -2.04% move.
What else has moved IOVA stock recently?
The two largest measured reactions before November 5, 2026: Oct 29, 2026, Iovance reports updated IOV-LUN-202 results and adds a precision TIL strategy for second-line metastatic non-small-cell lung cancer (-16.02% in 10 minutes); Sep 29, 2026, Iovance (IOVA) guidance update (-1.29% in 10 minutes).
Sources
-
IOVA headline and measured reaction, Nov 5, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Go live — 7 days for $29 Watch live headlines -- free